Achelios Therapeutics in Chapel Hill, NC has assembled a world-class pharmaceutical team with expertise in strategic management, business development, drug discovery, and clinical development. The team has extensive experience in pharmaceutical research, business, and corporate experience and is complemented by scientific and clinical advisors with broad expertise in medical research and clinical practice.
Crist J. Frangakis, Ph,D- President and Chief Executive Officer
Crist Frangakis is a founder and the CEO of Achelios Therapeutics. He has over 25 years of experience in pharmaceutical research and development, licensing, and business development. He led the discovery and development of several cardiovascular and metabolic drugs, serving as scientist and section head of research at Burroughs Wellcome and Glaxo. In addition, Crist had responsibility for pharmaceutical licensing and corporate development for 13 years at Johnson & Johnson and Bayer and closed on several successful major partnering deals. He received his Ph.D. in pharmacology from the University of Arizona and a B.S. in chemistry from the University of South Carolina. Crist is an author on over 70 publications published in several scientific journals.
Lucy Martindale, Chief Financial Officer
Lucy has over 30 years of experience in pharmaceutical and medical technology management for both private and public healthcare companies. She most recently served as Executive Vice President and Chief Financial Officer for LipoScience, Inc. a medical device company. At Liposcience, she was a member of the executive management team and negotiated and closed on multiple rounds of private financing before taking the company public in early 2013. She served as the public listed company CFO until the company was acquired in late 2014. Prior to Liposcience, Lucy was at Glaxo, Inc. and GlaxoWellcome for 17 years and held several financial management positions including Vice President of Financial Planning and Analysis for Glaxo, Inc. and Vice President, Finance Director for Global R&D for GlaxoWellcome. She has an M.B.A. from Campbell University and B.S. degree in Finance from the Indiana University Kelley School of Business.
John Fort, MD− Chief Medical Officer and Vice President of Clinical Operations
John joined Achelios in January 2016 as Chief Medical Officer and VP of Clinical Operations. John was the former head of clinical development at Pozen, the pharmaceutical company that developed the migraine therapy TreximetTM. At Pozen, John was a member of executive leadership team and managed all clinical activities through phase 3 and worked with regulatory agencies in the US and EU. Prior to Pozen, John was Vice-President of Clinical Affairs at Adalor working in the gastrointestinal area. He started his clinical development career at Searle, directing the development of the COX 2 inhibitor Celebrex. John has a M.D. from the University of Valencia, Spain and was a fellow at Thomas Jefferson University in Philadelphia. He also has an M.B.A. from Temple University.
James L. Yeager, RPh, PhD − Vice President Formulation Development
Jim is a pharmaceutical scientist who has actively developed new drug delivery technologies and new drug products for 30 years. He is an author, inventor, and expert in the field of topical drug delivery. Most recently, his research led to the development of new, innovative topical products for wound healing and the treatment of male and female sexual dysfunction, fungal and viral infections, and peripheral pain. Jim has an undergraduate degree in Pharmacy and a Ph.D. in industrial and Physical Pharmacy from Purdue University.
Mike S Fox, Chief Business and Commercial Officer
Mike Fox brings over 30 years of commercial experience in the pharmaceutical industry to Achelios. He has broad experience in sales, marketing and business development in both domestic and international markets. He was the Director of Marketing at two Ophthalmic Pharmaceutical companies and responsible for the launch of Pharmacia’s flagship brand Xalatan. Most recently he was the Global New Business Development leader for Janssen Pharmaceutical’s Cardiovascular and Metabolic Franchise which recently launched Invokana, a novel product for the treatment of type 2 diabetes. Mike has a M.Ed. from the University of Delaware and a B.S. in Marine Science from Stockton University.